Cannabidiol - Cardiol Therapeutics
Alternative Names: CardiolRx™; CardiolRx™100Latest Information Update: 30 Sep 2024
At a glance
- Originator Cardiol Therapeutics
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Cardiovascular disorders
- Phase II Myocarditis; Pericarditis
- Preclinical Diastolic heart failure
Most Recent Events
- 06 Sep 2024 Cardiol Therapeutics completes a phase-II trial in Pericarditis in USA (unspecified route) (NCT05494788)
- 14 Dec 2022 Cardiol Therapeutics terminates a phase II/III trial for Cardiovascular disorders (Prevention) in USA (PO) due to difficulty in recruitment (NCT04615949)
- 30 Nov 2022 Phase-II clinical trials in Pericarditis in USA (unspecified route) (NCT05494788)